

Dare Bioscience, Inc. (DARE)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001401914

Dare Bioscience, Inc.	
DARE; healthcare	
Grade	E weakest fifth of 371 graded peers percentile 96.5; sampling error 2.5 points; lower is stronger
Rank	358 of 371
Profitability	C/D percentile 61.4
Solvency	D/E percentile 80.2
Growth and financing	D/E percentile 81.2
Reliability	0.83 AUC filers with \$12.5M to \$120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$12.5M to \$120M assets total assets \$32.5M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution not computable: distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 26, 2026 197 days before the rescans; latest periodic filing 10-Q received Aug 13, 2026
Last close	\$0.76 2026-10-08; market equity \$11.5M
Price used in grade	None

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

[illegible]

Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

The terms "we," "us," "our," "Daré" or the "Company" refer collectively to Daré Bioscience, Inc. and its wholly-owned subsidiaries, unless otherwise stated or the context otherwise requires. All information in this report is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ending December 31 and the associated quarters, months and periods of those fiscal years. We are a purpose-driven health biotech company solely focused on

closing the gap in women's health between promising science and real-world solutions.

The fourteen inputs


lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 61.4						
Gross profitability		2.3%	32.2%	88.4	372	2025-12-31
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(12.9%)	(6.6%)	34.3	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 1
Solvency, sleeve percentile 80.2						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		(20.96)	(0.31)	74.2	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31
Current ratio		1.14x	2.96x	86.3	839	2025-12-31
Growth and financing, sleeve percentile 81.2						
Revenue growth, three-year compound		(53.1%)	10.0%	95.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		(9.5%)	2.1%	68.3	704	2025-12-31
Net share issuance, one year		64.5%	2.5%	79.3	634	2026-03-25

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 64.5%



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
353	VivoSim Labs, Inc. (VIVS)	95.1	E	dilution, short runway, late filer
354	ALX Oncology Holdings Inc. (ALXO)	95.4	E	dilution, short runway, degenerate inputs, fortress balance sheet
355	Biomerica Inc. (BMRA)	95.7	E	short runway
356	Bolt Biotherapeutics, Inc. (BOLT)	95.9	E	short runway, distress
357	Pfizer Inc. (PFE)	96.2	E	
358	Dare Bioscience, Inc. (DARE) <	96.5	E	dilution
359	Longeveron Inc. (LGVN)	96.8	E	short runway
360	Clene Inc. (CLNN)	97.0	E	dilution, distress
361	Agenus Inc. (AGEN)	97.3	E	dilution, short runway
362	Nektar Therapeutics (NKTR)	97.6	E	dilution, short runway
363	Vyome Holdings, Inc. (HIND)	97.8	E	dilution, late filer, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(63.8%)	8.0%	8
Distance from 52-week high	(76.4%)	(31.4%)	9
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(87.0%)	(1.0%)	6
Book value to price	(0.05)	0.28	9
Sales to price	0.09	0.31	23
Composite equity issuance, five years	135.5%	20.3%	84
Relative strength against the sector, log excess return	(1.23)	(0.14)	8

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail

Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	\$12.6M
Operating cash flow, four quarters	-\$11.3M
Months of runway	13.4
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$204,461

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$1.0M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
2	cost of revenue	us-gaap:CostOfRevenue	\$295,799	2025-12-31	2026-03-26	10-K	0001401914-26-000004
3	assets	us-gaap:Assets	\$32.5M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
4	net income	us-gaap:NetIncomeLoss	-\$13.4M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$9.9M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
6	assets	us-gaap:Assets	\$22.1M	2024-12-31	2026-03-26	10-K	0001401914-26-000004
7	current assets	us-gaap:AssetsCurrent	\$27.1M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
8	current liabilities	us-gaap:LiabilitiesCurrent	\$23.7M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$188.7M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
10	operating income	us-gaap:OperatingIncomeLoss	-\$13.6M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
11	book equity	us-gaap:StockholdersEquity	\$2.8M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
12	liabilities	us-gaap:Liabilities	\$29.6M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
13	operating income	us-gaap:OperatingIncomeLoss	-\$11.2M	2017-12-31	2019-04-01	10-K	0001401914-19-000015
14	interest expense	us-gaap:InterestExpense	\$322,629	2017-12-31	2018-03-28	10-K	0001564590-18-006989
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$9,784	2024-12-31	2026-03-26	10-K	0001401914-26-000004
16	revenue	us-gaap:Revenues	\$2.8M	2023-12-31	2024-03-28	10-K	0001401914-24-000016
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$10.0M	2022-12-31	2023-03-30	10-K	0001401914-23-000013
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$385,278	2025-12-31	2026-03-26	10-K	0001401914-26-000004
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$5.5M	2024-12-31	2026-03-26	10-K	0001401914-26-000004
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$573,046	2024-12-31	2026-03-26	10-K	0001401914-26-000004
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$38.9M	2023-12-31	2025-03-31	10-K	0001401914-25-000012
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$629,430	2023-12-31	2025-03-31	10-K	0001401914-25-000012
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$18.1M	2022-12-31	2024-03-28	10-K	0001401914-24-000016
24	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$63,069	2022-12-31	2024-03-28	10-K	0001401914-24-000016
25	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$1.6M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
26	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$18.5M	2025-12-31	2026-03-26	10-K	0001401914-26-000004
27	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-26	10-K	0001401914-26-000004
28	current assets	us-gaap:AssetsCurrent	\$18.4M	2024-12-31	2026-03-26	10-K	0001401914-26-000004
29	current liabilities	us-gaap:LiabilitiesCurrent	\$21.6M	2024-12-31	2026-03-26	10-K	0001401914-26-000004
30	assets	us-gaap:Assets	\$21.3M	2023-12-31	2025-03-31	10-K	0001401914-25-000012
31	assets	us-gaap:Assets	\$43.8M	2022-12-31	2024-03-28	10-K	0001401914-24-000016
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	14,559,502	2026-03-25	2026-03-26	10-K	0001401914-26-000004
33	shares outstanding	dei:EntityCommonStockSharesOutstanding	8,850,386	2025-03-28	2025-03-31	10-K	0001401914-25-000012